Abstract
We sought to explore whether trimetazidine addition reduces QT dispersion early after acute myocardial infarction. Prospectively, we randomized 60 consecutive patients with first acute ST elevation myocardial infarction to receive either trimetazidine 20 mg tid (trimetazidine group 30 patients), or placebo (placebo group 30 patients). QT dispersion and corrected QT dispersion were measured on day 3 and day 7 of admission. Patients were followed during hospitalization for the occurrence of ventricular arrhythmias (sustained ventricular tachycardia or ventricular fibrillation). QT dispersion and corrected QT dispersion were significantly lower in trimetazidine group in both days, compared to control group: day 3, 58±5 msec versus 78±6 msec, and 69±11 msec versus 91±10 msec, respectively, p < 0.001 for both; day 7, 41±7 msec versus 60±8 msec, and 47±9 msec versus 69±6 msec, respectively, p < 0.0001 for both. This finding was consistent in all prespecified subgroups. During hospital stay, 3 patients (10%) of the placebo group developed sustained ventricular tachycardia and 2 (6.6%) died of ventricular fibrillation, but no one in the trimetazidine group had such arrhythmias. Conclusion: In patients with first acute myocardial infarction, the addition of trimetazidine significantly reduced both QT dispersion and corrected QT dispersion and reduced the occurrence of ventricular arrhythmias throughout hospitalization.
Keywords: Trimetazidine, QT dispersion, myocardial infarction
Current Drug Therapy
Title: Trimetazidine: Does it Actually Reduce QT Dispersion After First Acute Myocardial Infarction?
Volume: 4 Issue: 1
Author(s): Khaled El-Meniawy, Hanan Hafez, Hala Bamatraf and Wail Nammas
Affiliation:
Keywords: Trimetazidine, QT dispersion, myocardial infarction
Abstract: We sought to explore whether trimetazidine addition reduces QT dispersion early after acute myocardial infarction. Prospectively, we randomized 60 consecutive patients with first acute ST elevation myocardial infarction to receive either trimetazidine 20 mg tid (trimetazidine group 30 patients), or placebo (placebo group 30 patients). QT dispersion and corrected QT dispersion were measured on day 3 and day 7 of admission. Patients were followed during hospitalization for the occurrence of ventricular arrhythmias (sustained ventricular tachycardia or ventricular fibrillation). QT dispersion and corrected QT dispersion were significantly lower in trimetazidine group in both days, compared to control group: day 3, 58±5 msec versus 78±6 msec, and 69±11 msec versus 91±10 msec, respectively, p < 0.001 for both; day 7, 41±7 msec versus 60±8 msec, and 47±9 msec versus 69±6 msec, respectively, p < 0.0001 for both. This finding was consistent in all prespecified subgroups. During hospital stay, 3 patients (10%) of the placebo group developed sustained ventricular tachycardia and 2 (6.6%) died of ventricular fibrillation, but no one in the trimetazidine group had such arrhythmias. Conclusion: In patients with first acute myocardial infarction, the addition of trimetazidine significantly reduced both QT dispersion and corrected QT dispersion and reduced the occurrence of ventricular arrhythmias throughout hospitalization.
Export Options
About this article
Cite this article as:
El-Meniawy Khaled, Hafez Hanan, Bamatraf Hala and Nammas Wail, Trimetazidine: Does it Actually Reduce QT Dispersion After First Acute Myocardial Infarction?, Current Drug Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157488509787081822
DOI https://dx.doi.org/10.2174/157488509787081822 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Single-cell RNA Sequencing: In-depth Decoding of Heart Biology and Cardiovascular Diseases
Current Genomics Evaluation of Echocardiographic Abnormalities in HIV Positive Patients Treated with Antiretroviral Medications
Infectious Disorders - Drug Targets Incidence and Prevalence of Hypothyroidism in Patients Affected by Chronic Heart Failure: Role of Amiodarone
Endocrine, Metabolic & Immune Disorders - Drug Targets Mechanism-based Modulator Discovery for Sirtuin-catalyzed Deacetylation Reaction
Mini-Reviews in Medicinal Chemistry Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis
Current Drug Targets Asymptomatic Lone Atrial Fibrillation - How can we Detect the Arrhythmia?
Current Pharmaceutical Design Novel Inflammatory Biomarkers in Coronary Artery Disease: Potential Therapeutic Approaches
Current Medicinal Chemistry The Impact of Traditional Chinese Medicine on Mitophagy in Disease Models
Current Pharmaceutical Design Epicardial and Intramyocardial Adipose Tissue: The Enemy within
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect
Current Drug Therapy Celiac Disease: An Emerging Epidemic
Current Nutrition & Food Science Do You See What I See: Recognition of Protozoan Parasites by Toll-Like Receptors
Current Immunology Reviews (Discontinued) The Long Way to Objectify Organ Damage Related to Cocaine Abuse: Oxidative Stress is the Main Culprit
Mini-Reviews in Organic Chemistry Endotherapia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tissue Engineering Techniques in Cardiac Repair and Disease Modelling
Current Pharmaceutical Design Potential Application of Non-flavonoid Phenolics in Diabetes: Antiinflammatory Effects
Current Medicinal Chemistry Lone Atrial Fibrillation: Electrophysiology, Risk Factors, Catheter Ablation and Other Non-pharmacologic Treatments
Current Pharmaceutical Design Antithrombotic Treatment after Atrial Fibrillation Ablation
Current Pharmaceutical Design The Role of Chymase in Vascular Remodeling and Tissue Fibrosis
Current Hypertension Reviews Investigating Mitochondrial Dysfunction to Increase Drug Safety in the Pharmaceutical Industry
Current Drug Targets